Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Rejection of immunogenic tumor clones is limited by clonal fraction.

Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AA, Schietinger A, Scheinberg DA.

Elife. 2018 Nov 30;7. pii: e41090. doi: 10.7554/eLife.41090.

2.

In situ augmentation of class I major histocompatibility antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma.

Elliott BE, Carlow DA, Ivimey L, Arnold M, Hampton N, Bosman P.

Cancer Res. 1987 Sep 15;47(18):4915-23.

3.

Immune selection in murine tumors. Ph.d thesis.

Svane IM, Engel AM.

APMIS Suppl. 2003;(106):1-46.

PMID:
12739251
4.

Outgrowth of stable class I major histocompatibility complex-expressing subsets from immunogenic variants of a murine mammary carcinoma: association with a differentially staining region on chromosome 9.

Elliott BE, Xu W, Brissette L, Deeley RG, Mudrik K, Marshall J, Vekemans M, Holden JJ.

Genes Chromosomes Cancer. 1991 Nov;3(6):433-42.

PMID:
1723292
5.
6.

MHC class I antigens, immune surveillance, and tumor immune escape.

Garcia-Lora A, Algarra I, Garrido F.

J Cell Physiol. 2003 Jun;195(3):346-55. Review.

PMID:
12704644
7.

Immunogenicity and tolerogenicity of self-major histocompatibility complex peptides.

Benichou G, Takizawa PA, Ho PT, Killion CC, Olson CA, McMillan M, Sercarz EE.

J Exp Med. 1990 Nov 1;172(5):1341-6.

8.

[Dendritic cells and immune function in cancer].

Chaux P.

Pathol Biol (Paris). 1995 Dec;43(10):897-903. Review. French.

PMID:
8786896
9.

Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.

Sivinski CL, Kohlgraf KG, VanLith ML, Morikane K, Tempero RM, Hollingsworth MA.

Cancer Immunol Immunother. 2002 Aug;51(6):327-40. Epub 2002 May 4.

PMID:
12111121
10.

Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.

NoeDominguez-Romero A, Zamora-Alvarado R, Servín-Blanco R, Pérez-Hernández EG, Castrillon-Rivera LE, Munguia ME, Acero G, Govezensky T, Gevorkian G, Manoutcharian K.

Hum Vaccin Immunother. 2014;10(11):3201-13. doi: 10.4161/hv.29679.

12.

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.

Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP.

J Exp Med. 1998 Jul 20;188(2):277-86.

13.

Immunologic mechanisms of antitumor activity.

Foss FM.

Semin Oncol. 2002 Jun;29(3 Suppl 7):5-11. Review.

PMID:
12068382
14.

Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.

Kaumaya PT, Kobs-Conrad S, Seo YH, Lee H, VanBuskirk AM, Feng N, Sheridan JF, Stevens V.

J Mol Recognit. 1993 Jun;6(2):81-94.

PMID:
7508238
15.
16.

Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.

Martin SD, Brown SD, Wick DA, Nielsen JS, Kroeger DR, Twumasi-Boateng K, Holt RA, Nelson BH.

PLoS One. 2016 May 18;11(5):e0155189. doi: 10.1371/journal.pone.0155189. eCollection 2016.

17.

Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.

Chornoguz O, Gapeev A, O'Neill MC, Ostrand-Rosenberg S.

Mol Cell Proteomics. 2012 Nov;11(11):1457-67. doi: 10.1074/mcp.M112.019232. Epub 2012 Aug 31.

18.

Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.

Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG.

Prostate. 2002 Nov 1;53(3):183-91.

20.

Mechanisms of indirect allorecognition in graft rejection: class II MHC allopeptide-specific T cell clones transfer delayed-type hypersensitivity responses in vivo.

Chen W, Murphy B, Waaga AM, Willett TA, Russell ME, Khoury SJ, Sayegh MH.

Transplantation. 1996 Sep 27;62(6):705-10.

PMID:
8824464

Supplemental Content

Support Center